Skip to main content
. 2019 May 16;4(10):e125052. doi: 10.1172/jci.insight.125052

Figure 9. scAAV.CNP.Venus.Plp1miRNA treatment improved astrogliosis in Plp1-Tg mice.

Figure 9

(A) Immunostaining for astrocyte marker GFAP in the coronal brain sections of P25 Wt+miRneg mice (top row), Tg+miRneg mice (middle row), and Tg+Plp1miRNA mice (bottom row). Low-magnification images (first and second columns, scale bar: 1 mm) and the high-magnification images (scale bar: 50 μm) of the CC (third column) and IC (fourth column) are shown. (B) Quantification of the percentage of GFAP-positive areas in CC sections and IC sections (n = 5 mice per group). Region of interest (ROI) was 700 μm × 100 μm in the CC and 15,1976 μm2 in the IC. Statistical significance was determined using 1-way ANOVA with Bonferroni’s post hoc test. *P < 0.05; **P < 0.01.